Alzinova AB (publ) Logo

Alzinova AB (publ)

ALZ.ST

(1.5)
Stock Price

3,92 SEK

-205.76% ROA

-16.27% ROE

-7.96x PER

Market Cap.

288.896.220,00 SEK

0.77% DER

0% Yield

-503.31% NPM

Alzinova AB (publ) Stock Analysis

Alzinova AB (publ) Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Alzinova AB (publ) Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.78x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Assets Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

4 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

5 ROE

Negative ROE (-14.29%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (-41.54%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Alzinova AB (publ) Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Alzinova AB (publ) Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Alzinova AB (publ) Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Alzinova AB (publ) Revenue
Year Revenue Growth
2012 2.189.961
2013 839.373 -160.9%
2014 954.334 12.05%
2015 998.387 4.41%
2016 5.252.951 80.99%
2017 5.790.962 9.29%
2018 9.360.057 38.13%
2019 6.808.837 -37.47%
2020 14.898.034 54.3%
2021 17.321.738 13.99%
2022 16.633.432 -4.14%
2023 0 0%
2023 270.000 100%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Alzinova AB (publ) Research and Development Expenses
Year Research and Development Expenses Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Alzinova AB (publ) General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 5.548.497 100%
2017 5.729.835 3.16%
2018 10.726.729 46.58%
2019 8.764.417 -22.39%
2020 17.233.465 49.14%
2021 19.025.906 9.42%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Alzinova AB (publ) EBITDA
Year EBITDA Growth
2012 8.694
2013 -3.580 342.85%
2014 -11.961 70.07%
2015 -3.404.850 99.65%
2016 -2.955.303 -15.21%
2017 -2.489.943 -18.69%
2018 -4.175.862 40.37%
2019 -6.177.477 32.4%
2020 -6.498.638 4.94%
2021 -7.519.352 13.57%
2022 -13.068.448 42.46%
2023 -14.116.000 7.42%
2023 -16.382.000 13.83%
2024 -19.068.000 14.09%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Alzinova AB (publ) Gross Profit
Year Gross Profit Growth
2012 193.068
2013 177.312 -8.89%
2014 234.235 24.3%
2015 998.387 76.54%
2016 10.143.019 90.16%
2017 10.935.217 7.24%
2018 18.707.135 41.55%
2019 13.617.674 -37.37%
2020 29.796.068 54.3%
2021 34.643.476 13.99%
2022 33.266.864 -4.14%
2023 13.200.000 -152.02%
2023 -16.522.000 179.89%
2024 11.540.000 243.17%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Alzinova AB (publ) Net Profit
Year Net Profit Growth
2012 -1.855.299
2013 -335.728 -452.62%
2014 -471.512 28.8%
2015 -3.407.270 86.16%
2016 -2.964.052 -14.95%
2017 -2.508.098 -18.18%
2018 -4.189.311 40.13%
2019 -6.202.329 32.46%
2020 -6.500.476 4.59%
2021 -7.584.660 14.29%
2022 -13.069.944 41.97%
2023 -14.196.000 7.93%
2023 -16.480.000 13.86%
2024 -19.504.000 15.5%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Alzinova AB (publ) Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 -1
2013 0 0%
2014 0 0%
2015 -1 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 -1 0%
2020 0 0%
2021 0 0%
2022 -1 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Alzinova AB (publ) Free Cashflow
Year Free Cashflow Growth
2012 0
2013 0 0%
2014 -715.192 100%
2015 -4.625.370 84.54%
2016 -7.714.891 40.05%
2017 -7.157.874 -7.78%
2018 -13.379.071 46.5%
2019 -10.867.589 -23.11%
2020 -21.169.115 48.66%
2021 -27.141.504 22%
2022 -26.947.169 -0.72%
2023 -3.675.000 -633.26%
2023 -34.817.000 89.44%
2024 -8.020.000 -334.13%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Alzinova AB (publ) Operating Cashflow
Year Operating Cashflow Growth
2012 0
2013 0 0%
2014 -715.192 100%
2015 -3.209.590 77.72%
2016 -2.764.089 -16.12%
2017 -2.130.802 -29.72%
2018 -3.967.356 46.29%
2019 -3.975.735 0.21%
2020 -6.265.728 36.55%
2021 -9.819.766 36.19%
2022 -10.313.736 4.79%
2023 -375.000 -2650.33%
2023 -15.213.000 97.54%
2024 -5.135.000 -196.26%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Alzinova AB (publ) Capital Expenditure
Year Capital Expenditure Growth
2012 0
2013 0 0%
2014 0 0%
2015 1.415.780 100%
2016 4.950.802 71.4%
2017 5.027.072 1.52%
2018 9.411.715 46.59%
2019 6.891.854 -36.56%
2020 14.903.387 53.76%
2021 17.321.738 13.96%
2022 16.633.433 -4.14%
2023 3.300.000 -404.04%
2023 19.604.000 83.17%
2024 2.885.000 -579.51%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Alzinova AB (publ) Equity
Year Equity Growth
2012 947.417
2013 723.689 -30.91%
2014 1.552.678 53.39%
2015 20.633.945 92.48%
2016 31.899.973 35.32%
2017 29.391.875 -8.53%
2018 63.752.997 53.9%
2019 59.110.774 -7.85%
2020 96.023.765 38.44%
2021 88.471.759 -8.54%
2022 105.533.217 16.17%
2023 113.858.000 7.31%
2023 118.589.000 3.99%
2024 104.020.000 -14.01%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Alzinova AB (publ) Assets
Year Assets Growth
2012 1.117.199
2013 1.451.714 23.04%
2014 2.141.930 32.22%
2015 22.199.800 90.35%
2016 33.312.586 33.36%
2017 31.720.519 -5.02%
2018 66.087.745 52%
2019 63.531.184 -4.02%
2020 100.815.659 36.98%
2021 91.691.392 -9.95%
2022 111.621.075 17.85%
2023 123.189.000 9.39%
2023 126.328.000 2.48%
2024 112.399.000 -12.39%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Alzinova AB (publ) Liabilities
Year Liabilities Growth
2012 169.782
2013 728.025 76.68%
2014 589.252 -23.55%
2015 1.565.855 62.37%
2016 1.412.613 -10.85%
2017 2.328.644 39.34%
2018 2.334.748 0.26%
2019 4.420.410 47.18%
2020 4.791.894 7.75%
2021 3.219.633 -48.83%
2022 6.087.858 47.11%
2023 9.331.000 34.76%
2023 7.739.000 -20.57%
2024 8.379.000 7.64%

Alzinova AB (publ) Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.08
Net Income per Share
-0.41
Price to Earning Ratio
-7.96x
Price To Sales Ratio
80.25x
POCF Ratio
-8.5
PFCF Ratio
-9.14
Price to Book Ratio
1.39
EV to Sales
79.09
EV Over EBITDA
-15.88
EV to Operating CashFlow
-16.78
EV to FreeCashFlow
-9.01
Earnings Yield
-0.13
FreeCashFlow Yield
-0.11
Market Cap
0,29 Bil.
Enterprise Value
0,28 Bil.
Graham Number
4.62
Graham NetNet
-0.01

Income Statement Metrics

Net Income per Share
-0.41
Income Quality
0.94
ROE
-0.16
Return On Assets
-0.16
Return On Capital Employed
-0.17
Net Income per EBT
1
EBT Per Ebit
1
Ebit per Revenue
-5.02
Effective Tax Rate
0.19

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
-0.08
Operating Profit Margin
-5.02
Pretax Profit Margin
-5.03
Net Profit Margin
-5.03

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.38
Free CashFlow per Share
-0.71
Capex to Operating CashFlow
-0.86
Capex to Revenue
4.06
Capex to Depreciation
0
Return on Invested Capital
-0.14
Return on Tangible Assets
-2.06
Days Sales Outstanding
387.1
Days Payables Outstanding
210.82
Days of Inventory on Hand
0
Receivables Turnover
0.94
Payables Turnover
1.73
Inventory Turnover
0
Capex per Share
0.33

Balance Sheet

Cash per Share
0,11
Book Value per Share
2,34
Tangible Book Value per Share
0.01
Shareholders Equity per Share
2.34
Interest Debt per Share
0.02
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
0.23
Current Ratio
1.16
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
104819000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.92
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Alzinova AB (publ) Dividends
Year Dividends Growth

Alzinova AB (publ) Profile

About Alzinova AB (publ)

Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.

CEO
Dr. Carol Routledge
Employee
5
Address
Pepparedsleden 1
Mölndal, 431 83

Alzinova AB (publ) Executives & BODs

Alzinova AB (publ) Executives & BODs
# Name Age
1 Dr. Carol Routledge
Acting Chief Executive Officer & Director
70

Alzinova AB (publ) Competitors

AlzeCure Pharma AB (publ) Logo
AlzeCure Pharma AB (publ)

ALZCUR.ST

(1.0)
BioArctic AB (publ) Logo
BioArctic AB (publ)

BIOA-B.ST

(1.8)
Cantargia AB (publ) Logo
Cantargia AB (publ)

CANTA.ST

(1.5)
Diamyd Medical AB (publ) Logo
Diamyd Medical AB (publ)

DMYD-B.ST

(0.8)
Saniona AB (publ) Logo
Saniona AB (publ)

SANION.ST

(0.8)